Praxis Precision Medicines to Participate in Upcoming Fireside Chat
Rhea-AI Summary
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, has announced its upcoming participation in a virtual event. CEO Marcio Souza will engage in a fireside chat hosted by Truist Securities analyst Joon Lee on August 5, 2025 at 10:00 AM EST.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, PRAX declined 6.46%, reflecting a notable negative market reaction. Argus tracked a peak move of +30.1% during that session. Argus tracked a trough of -20.0% from its starting point during tracking. Our momentum scanner triggered 40 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $76M from the company's valuation, bringing the market cap to $1.10B at that time. Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that CEO Marcio Souza will be participating a virtual fireside chat hosted by Truist Securities analyst Joon Lee on August 5, 2025 at 10:00amEST.
The registration link can be found here.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, Instagram, LinkedIn and Twitter/X.
Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry Life Science Advisors Daniel@lifesciadvisors.com 617-430-7576
FAQ
When is the Praxis Precision Medicines (PRAX) fireside chat scheduled for?
Who will represent Praxis Precision Medicines at the Truist Securities fireside chat?
What is Praxis Precision Medicines' (PRAX) main focus area?
Who is hosting the PRAX fireside chat?
